Citations

Clear

623 citation(s) found for "Torres, V".

The longitudinal risk of hemorrhage of melanoma brain metastases after Gamma Knife radiosurgery
Hong, Sukwoo , Bouchal, Samantha M. , Riviere-Cazaux, Cécile , Pumford, Andrew D. , Brown, Paul D. , Yan, Elizabeth , Stafford, Scott L., Link, Michael J., Jusué-Torres, Ignacio , Pollock, Bruce E. , Jusue-Torres, Ignacio , Bouchal, Samantha M , Bauman, Megan M. J. , Markovic, Svetomir N. , Link, Michael J. , Burns, Terry C. , Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | September 30, 2023 | Volume: 140 | Issue: 4 | Pages: 938-948

10.3171/2023.7.jns231225 | PMID 37878000 Get It

OBJECTIVE The objective of this study was to analyze the hemorrhagic risk of melanoma brain metastases after Gamma Knife radiosurgery (GKRS). METHODS A prospective institutional database was retrospectively queried to identify patients who underwent GKRS for melanoma brain metastases between 1990 and 2021. Lesional hemorrhage was defined as definite or possible based on radiologists’ readings, and severity was graded according to Common Terminology Criteria for Adverse Events. RESULTS Two hundred ninety-one patients with 1083 lesions treated in 419 sessions were identified. The mean (± SD) patient age was 60 ± 15 years, and 61% were male. The median follow-up period for overall survival (OS) was 11 (range 0–214) months with 581 patient-years. Definite/possible lesional hemorrhages occurred in 13% of lesions, with grade 3 hemorrhages observed in 4% of lesions. Surgical intervention was required in 2% of cases (5% of patients), and all resected lesions were pathologically consistent with melanoma. A decreased risk of definite/possible lesional hemorrhage was associated with a later time period between 2015 and 2021 (OR 0.45, 95% CI 0.266–0.75, p = 0.0021), increased marginal dose (OR 0.91, 95% CI 0.83–0.99, p = 0.037), antiplatelet use post-GKRS (OR 0.195, 95% CI 0.083–0.46, p < 0.001), and whole-brain radiotherapy (WBRT; OR 0.53, 95% CI 0.344–0.82, p = 0.0042). After 2015, more patients received anticoagulation, B-Raf proto-oncogene inhibitors, and immune checkpoint inhibitors, and fewer received bevacizumab (p < 0.001). The cumulative risk of lesional hemorrhage was 17%–20% at 36 months from GKRS, with 95%–96% of cases occurring within 12 months. The median patient OS was 11 (95% CI 9–13) months, and multivariate Cox regression analysis revealed that antiplatelet agents (hazard ratio [HR] 0.66, 95% CI 0.45–0.96, p = 0.031) and immune checkpoint inhibitors (HR 0.35, 95% CI 0.26–0.48, p < 0.001) were associated with longer OS, while WBRT (HR 1.36, 95% CI 1.02–1.81, p = 0.037) and definite/possible hemorrhage (HR 1.39, 95% CI 1.04–1.85, p = 0.024) were associated with shorter OS. CONCLUSIONS The definite hemorrhage risk of melanoma brain metastases after GKRS was 17% in the first 3 years and 95% of the lesional hemorrhage occurred within the 1st year. Surgical intervention was needed in 5% of patients. Antiplatelet agents and immune checkpoint inhibitors were associated with improved OS, while definite/possible hemorrhage was associated with worse OS.
Benefits and Challenges of Remote Patient Monitoring as Perceived by Health Care Practitioners: A Systematic Review
Serrano, Luiza Palmieri , Maita, Karla C. , Garcia, John P, Eldaly, Abdullah S. , Haider, Clifton R. , Felton, Christopher L. , Maniaci, Michael J. , Torres-Guzman, Ricardo A, Maniaci, Michael J , Forte, Antonio Jorge , Felton, Christopher L , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Paulson, Margaret R. , Forte, Antonio J.

Mayo Clinic

The Permanente Journal | September 22, 2023 | Volume: 27 | Issue: 4 | Pages: 100-111

10.7812/tpp/23.022 | PMID 37735970 Get It

Machine Learning Algorithms Predict Long-Term Postoperative Opioid Misuse: A Systematic Review
Emam, Omar S. , Eldaly, Abdullah S. , Maita, Karla C. , Brown, Sally A., Haider, Clifton R. , Torres-Guzman, Ricardo A, Anne Brown, Sally, Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Garcia, John P. , Brown, Sally Anne, Forte, Antonio J.

Mayo Clinic

The American Surgeon™ | September 21, 2023 | Volume: 90 | Issue: 1 | Pages: 140-151

10.1177/00031348231198112 | PMID 37732536 Get It

Introduction A steadily rising opioid pandemic has left the US suffering significant social, economic, and health crises. Machine learning (ML) domains have been utilized to predict prolonged postoperative opioid (PPO) use. This systematic review aims to compile all up-to-date studies addressing such algorithms’ use in clinical practice. Methods We searched PubMed/MEDLINE, EMBASE, CINAHL, and Web of Science using the keywords “machine learning,” “opioid,” and “prediction.” The results were limited to human studies with full-text availability in English. We included all peer-reviewed journal articles that addressed an ML model to predict PPO use by adult patients. Results Fifteen studies were included with a sample size ranging from 381 to 112898, primarily orthopedic-surgery-related. Most authors define a prolonged misuse of opioids if it extends beyond 90 days postoperatively. Input variables ranged from 9 to 23 and were primarily preoperative. Most studies developed and tested at least two algorithms and then enhanced the best-performing model for use retrospectively on electronic medical records. The best-performing models were decision-tree-based boosting algorithms in 5 studies with AUC ranging from .81 to .66 and Brier scores ranging from .073 to .13, followed second by logistic regression classifiers in 5 studies. The topmost contributing variable was preoperative opioid use, followed by depression and antidepressant use, age, and use of instrumentation. Conclusions ML algorithms have demonstrated promising potential as a decision-supportive tool in predicting prolonged opioid use in post-surgical patients. Further validation studies would allow for their confident incorporation into daily clinical practice.
Artificial Intelligence Models in Health Information Exchange: A Systematic Review of Clinical Implications
Maniaci, Michael J. , Haider, Clifton R. , Maita, Karla C. , Lunde, Julianne J. , Coffey, Jordan , Forte, Antonio J. , Maniaci, Michael J , Torres-Guzman, Ricardo A, Coffey, Jordan D , Forte, Antonio Jorge , Borna, Sahar , Torres‐Guzman, Ricardo A. , Ávila, Francisco R. , Demaerschalk, Bart M.

Mayo Clinic

Healthcare | September 19, 2023 | Volume: 11 | Issue: 18 | Pages: 2584

10.3390/healthcare11182584 | PMID 37761781 Get It

Electronic health record (EHR) systems collate patient data, and the integration and standardization of documents through Health Information Exchange (HIE) play a pivotal role in refining patient management. Although the clinical implications of AI in EHR systems have been extensively analyzed, its application in HIE as a crucial source of patient data is less explored. Addressing this gap, our systematic review delves into utilizing AI models in HIE, gauging their predictive prowess and potential limitations. Employing databases such as Scopus, CINAHL, Google Scholar, PubMed/Medline, and Web of Science and adhering to the PRISMA guidelines, we unearthed 1021 publications. Of these, 11 were shortlisted for the final analysis. A noticeable preference for machine learning models in prognosticating clinical results, notably in oncology and cardiac failures, was evident. The metrics displayed AUC values ranging between 61% and 99.91%. Sensitivity metrics spanned from 12% to 96.50%, specificity from 76.30% to 98.80%, positive predictive values varied from 83.70% to 94.10%, and negative predictive values between 94.10% and 99.10%. Despite variations in specific metrics, AI models drawing on HIE data unfailingly showcased commendable predictive proficiency in clinical verdicts, emphasizing the transformative potential of melding AI with HIE. However, variations in sensitivity highlight underlying challenges. As healthcare’s path becomes more enmeshed with AI, a well-rounded, enlightened approach is pivotal to guarantee the delivery of trustworthy and effective AI-augmented healthcare solutions.
OS09.5.A BREAKING DOWN BARRIERS: THE IMPACT OF BLOOD-BRAIN BARRIER DISRUPTION ON THE GLIOMA METABOLIC MICROENVIRONMENT, IN SITU
Riviere-Cazaux, Cécile , Carlstrom, Luke, Munoz-Casabella, Amanda , Gharibi-Loron, Ali, Brown, Dennis , Miller, Kai J. , White, J. Courtland, Himes, Brent, Jusué-Torres, Ignacio , Ikram, S. , Hirte, Renee, Oh, Ju-Hee, Elmquist, William F. , Vaubel, Rachel, Warrington, A.P., Kizilbash, Sani H. , Kizilbash, Sani H , Jusue-Torres, Ignacio , Carlstrom, L, Rajani, Karishma , Rahman, Masum , Brown, D, Ikram, S, Ransom, S. M. , Sarkaria, Jann N. , Rodriguez, Moses , Warrington, A, Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.062 Get It

Abstract BACKGROUND The microenvironment of glioblastoma is complex and defined in part by protumorigenic metabolic changes. Within this microenvironment, blood-brain barrier disruption is often associated with the most aggressive portions of the tumor. To date, the metabolic tumor microenvironments of enhancing, blood-brain barrier (BBB) disrupted portions of gliomas, as compared to BBB-intact tumor, remain poorly understood. Specifically, it is unclear if the associated blood-brain barrier disruption merely reflects or functionally supports tumor aggressiveness. METHODS Intra-operative high-molecular weight microdialysis was utilized under an investigational device exemption (NCT NCT04047264) to sample the extracellular metabolome of radiographically diverse regions during fifteen neurosurgical resections. The global extracellular metabolome of recovered microdialysate from contrast-enhancing and non-enhancing tumor, as well as brain adjacent to tumor, was evaluated via ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) on the Metabolon platform and assessed using enrichment and correlation analyses. RESULTS Among 162 named metabolites identified via ultra-performance liquid chromatography tandem mass spectrometry, a novel glioma-associated metabolite, guanidinoacetate (GAA), was 126.32x higher in enhancing tumor than in adjacent brain and 13.63x higher in non-enhancing tumor than brain. Forty-eight additional metabolites were 2.05-10.18x more abundant in enhancing tumor than brain, including carnitine family members and all nine large neutral amino acids. Except for GAA and 2-hydroxyglutarate in IDH-mutant gliomas, differences between non-enhancing tumor and brain microdialysate were comparatively modest and less consistent, suggesting heterogeneity in the glioma metabolic microenvironment of blood-brain barrier (BBB) intact areas as compared to BBB-disrupted portions of gliomas. Interestingly, the enhancing but not the non-enhancing glioma metabolome was significantly enriched for plasma-associated metabolites, largely comprising amino acids and carnitines. CONCLUSION Our patient-derived data suggest that the BBB-disrupted metabolome of high-grade gliomas is characterized by metabolite diffusion from circulation into the tumor microenvironment. Further studies are ongoing to determine how this alteration in the glioma extracellular metabolome impacts glioma behavior and how it could be therapeutically targeted via BBB-modulating drugs.
Prognostic and Diagnostic Utility of Serum Biomarkers in Pediatric Traumatic Brain Injury
Pareja, Jennifer C. Muñoz , Vaccari, Juan Pablo de Rivero , Chavez, Maria Mateo , Kerrigan, Maria, Pringle, Charlene , Guthrie, Kourtney, Swaby, Kathryn, Coto, Jennifer , Avery, K. Leslie , Ghosh, Suman , Dhanashree, Rajderkar, Shanmugham, Prashanth, Lautenslager, Lauren A. , Faulkenberry, Shannon, Zabala, María C. Pareja , Fakhri, Nora Al, Loor-Torres, Ricardo , Governale, Lance S., Blatt, Jason E. , Gober, Joslyn , Perez, Paula Karina, O’Phelan, Kristine , Dietrich, W. Dalton , Mateo Chavez, Maria B , Pringle, Charlene P , de Rivero Vaccari, Juan Pablo , Kobeissy, Firas , Solano, Juan, McCrea, Heather J. , Thorson, Chad M. , Keane, Robert W. , Wang, Kevin

Mayo Clinic

Journal of Neurotrauma | August 30, 2023 | Volume: 41 | Issue: 1-2 | Pages: 106-122

10.1089/neu.2023.0039 | PMID 37646421 Get It

Traumatic brain injury (TBI) remains a major cause of morbidity and death among the pediatric population. Timely diagnosis, however, remains a complex task because of the lack of standardized methods that permit its accurate identification. The aim of this study was to determine whether serum levels of brain injury biomarkers can be used as a diagnostic and prognostic tool in this pathology. This prospective, observational study collected and analyzed the serum concentration of neuronal injury biomarkers at enrollment, 24h and 48h post-injury, in 34 children ages 0–18 with pTBI and 19 healthy controls (HC). Biomarkers included glial fibrillary acidic protein (GFAP), neurofilament protein L (NfL), ubiquitin-C-terminal hydrolase (UCH-L1), S-100B, tau and tau phosphorylated at threonine 181 (p-tau181). Subjects were stratified by admission Glasgow Coma Scale score into two categories: a combined mild/moderate (GCS 9–15) and severe (GCS 3–8). Glasgow Outcome Scale-Extended (GOS-E) Peds was dichotomized into favorable (≤4) and unfavorable (≥5) and outcomes. Data were analyzed utilizing Prism 9 and R statistical software. The findings were as follows: 15 patients were stratified as severe TBI and 19 as mild/moderate per GCS. All biomarkers measured at enrollment were elevated compared with HC. Serum levels for all biomarkers were significantly higher in the severe TBI group compared with HC at 0, 24, and 48h. The GFAP, tau S100B, and p-tau181 had the ability to differentiate TBI severity in the mild/moderate group when measured at 0h post-injury. Tau serum levels were increased in the mild/moderate group at 24h. In addition, NfL and p-tau181 showed increased serum levels at 48h in the aforementioned GCS category. Individual biomarker performance on predicting unfavorable outcomes was measured at 0, 24, and 48h across different GOS-E Peds time points, which was significant for p-tau181 at 0h at all time points, UCH-L1 at 0h at 6–9 months and 12 months, GFAP at 48h at 12 months, NfL at 0h at 12 months, tau at 0h at 12 months and S100B at 0h at 12 months. We concluded that TBI leads to increased serum neuronal injury biomarkers during the first 0–48h post-injury. A biomarker panel measuring these proteins could aid in the early diagnosis of mild to moderate pTBI and may predict neurological outcomes across the injury spectrum.
P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
Ajufo, Helen, Harrison, Claire , Palmer, Jeanne , Derkach, Andrii, Roman‐Torres, Karisse, Buckley, Sarah , Rampal, Raajit K. , Bewersdorf, Jan Philipp , Palandri, Francesca , Mascarenhas, John , Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Дмитрович, Деркач Андрій

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e44640da

10.1097/01.hs9.0000971016.44640.da Get It

Healthcare Workers’ Experience with an Artificial Intelligence Virtual Assistant for Plastic Surgery Patients
Maita, Karla C. , Eldaly, Abdullah S. , Serrano, Luiza Palmieri , Emam, Omar S. , Ho, Olivia A. , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Garcia, John P. , Forte, Antonio J.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 28, 2023 | Volume: 10 | Issue: 10S | Pages: 62-62

10.1097/01.gox.0000898632.91987.63 Get It

Development of a Scalp Radiation Dermatitis Model in Mice
Maita, Karla C. , Eldaly, Abdullah S. , Serrano, Luiza Palmieri , Emam, Omar S. , Ho, Olivia A. , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Garcia, John , Forte, Antonio J. , Sarabia-Estrada, Rachel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 28, 2023 | Volume: 10 | Issue: 10S | Pages: 65-65

10.1097/01.gox.0000898648.11720.3c Get It

Novel Benchmark Values for Open Major Anatomic Liver Resection in Non-cirrhotic Patients
Silva, Richard X. Sousa Da , Breuer, Eva , Shankar, Sadhana , Hołówko, Wacław , Coelho, João Santos, Jeddou, Heithem , Sugiura, Teiichi , Ghallab, Mohammed, Silva, Doris Da, Watanabe, Genki , Sakai, Nozomu , Addeo, Pietro , Tzedakis, Stylianos , Bartsch, F. , Balcer, Kaja, Lim, Chétana , Werey, Fabien, López, Víctor , Montero, Luciana Peralta, Clariá, Rodrigo Sanchez, Leiting, Jennifer L. , Vachharajani, Neeta , Hopping, Eve , Andel, Daan, Hagendoorn, Jeroen , Psica, Alicja , Ahn, Keun Soo , Montes, Leonardo A., Gunasekaran, Ganesh , Alcázar, C. , Lim, Jin Hong , Haroon, Muhammad, Lü, Qian , Castaldi, Antonio , Orimo, Tatsuya , Abadía, Teresa, Hasan, Josefina Dib, Kaufmann, Emmanuele F., Wilde, Roeland F. de , Boggi, Ugo , Hernandez‐Alejandro, Roberto, Serrablo, Alejandro , Taketomi, Akinobu , Dong, Jiahong , Hanif, Faisal, Park, Joon Seong , Schwartz, Myron , Ramisch, Diego , Oliveira, Michelle de , Oldhafer, K.J., Kang, Koo Jeong , Lodge, P., Rinkes, Inne H. M. Borel, Thomson, John‐Edwin , Goh, Su Kah , Chapman, William C. , Pekolj, Juan , Scatton, Olivier , Truant, Stéphanie , Lang, Hauke , Bachellier, Philippe , Otsuka, Masayuki, Popescu, Irinel , Cherqui, Daniel , Uesaka, Katsuhiko , Marques, Hugo P. , Grąt, Michał , Petrowsky, Henrik , Ebata, Tomoki , Prachalias, Andreas , Clavien, Pierre‐Alain , Kauffmann, Emanuele F. , Leiting, Jennifer, Chapman, William C , Shankar, Sadhana , Kawakatsu, Shoji , Botea, Florin , Torres, Orlando Jorge Martins , Hirano, Satoshi , Ravaioli, Matteo , Reese, Tim , Montes, Leonardo A., Castaldi, Antonio, Moeckli, Beat , Ruffolo, Luis I. , Hasan, Josefina Dib, Ratti, Francesca , Polak, Wojciech G. , Aldrighetti, Luca , McCormack, Lucas , Toso, Christian , Gugenheim, Jean , Ramia, José Manuel , Cescon, Matteo , Rinkes, Inne H.M. Borel , Noji, Takehiro , Cleary, Sean P. , Regimbeau, Jean‐Marc , Fuks, David , Hasegawa, Kiyoshi , Lesurtel, Mickaël , Adam, René , Boudjéma, Karim , Robles, R

Mayo Clinic

Annals of Surgery | July 19, 2023 | Volume: 278 | Issue: 5 | Pages: 748-755

10.1097/sla.0000000000006012 | PMID 37465950 Get It

Objective: This study aims at establishing benchmark values for best achievable outcomes following open major anatomic hepatectomy for liver tumors of all dignities. Background: Outcomes after open major hepatectomies vary widely lacking reference values for comparisons among centers, indications, types of resections, and minimally invasive procedures. Methods: A standard benchmark methodology was used covering consecutive patients, who underwent open major anatomic hepatectomy from 44 high-volume liver centers from 5 continents over a 5-year period (2016–2020). Benchmark cases were low-risk non-cirrhotic patients without significant comorbidities treated in high-volume centers (≥30 major liver resections/year). Benchmark values were set at the 75th percentile of median values of all centers. Minimum follow-up period was 1 year in each patient. Results: Of 8044 patients, 2908 (36%) qualified as benchmark (low-risk) cases. Benchmark cutoffs for all indications include R0 resection ≥78%; liver failure (grade B/C) ≤10%; bile leak (grade B/C) ≤18%; complications ≥grade 3 and CCI ® ≤46% and ≤9 at 3 months, respectively. Benchmark values differed significantly between malignant and benign conditions so that reference values must be adjusted accordingly. Extended right hepatectomy (H1, 4-8 or H4-8) disclosed a higher cutoff for liver failure, while extended left (H1-5,8 or H2-5,8) were associated with higher cutoffs for bile leaks, but had superior oncologic outcomes, when compared to formal left hepatectomy (H1-4 or H2-4). The minimal follow-up for a conclusive outcome evaluation following open anatomic major resection must be 3 months. Conclusion: These new benchmark cutoffs for open major hepatectomy provide a powerful tool to convincingly evaluate other approaches including parenchymal-sparing procedures, laparoscopic/robotic approaches, and alternative treatments, such as ablation therapy, irradiation, or novel chemotherapy regimens.